Posted in | News

NanoViricides Developing FluCide to Work Against All Influenza Types and Subtypes

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it is developing FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.

The Company has previously announced excellent results in both animal studies and cell culture studies against widely different influenza subtypes and strains. If these results are confirmed in further animal and human studies, then FluCide would likely be considered the best ever drug effective against all influenzas. The Company is communicating its capabilities to various agencies involved in the current epidemic response.

The current swine flu outbreak is significant in that the H1N1 virus causing it is novel (http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/apr2109swine.html). The US Department of Homeland Security has declared a Swine Flu Emergency yesterday. The WHO has said that the outbreak is an emergency of international concern (http://www.upi.com/Health_News/2009/04/26/DHS-declares-swine-flu-emergency/UPI-53711240725694/). The pig is known to be a transitional species for influenza viruses. That means re-assortment (i.e. mixing) of genes from bird flu, human flu, and swine flu viruses can take place in pigs. This can lead to more lethal, drug resistant novel strains to emerge from different existing ones.

"Nanoviricides(™) have clear advantages over antibodies and vaccines as antiviral strategies," said Dr. Diwan, President of NanoViricides. Antibodies are relatively specific to a particular virus strain or subtype. It is well known that HIV and influenza viruses among many others, quickly escape antibodies. Vaccines depend upon the development of antibodies by the host, and thus, cannot protect efficiently against those viruses which are continually changing their character, such as the influenza virus. Influenza vaccines in particular have to be developed with the strain that is expected to infect in the next year’s cycle. It is well known that this is not a failure-proof strategy for epidemic-causing strains that are novel.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    NanoViricides, Inc. (2019, February 14). NanoViricides Developing FluCide to Work Against All Influenza Types and Subtypes. AZoNano. Retrieved on April 18, 2024 from https://www.azonano.com/news.aspx?newsID=11122.

  • MLA

    NanoViricides, Inc. "NanoViricides Developing FluCide to Work Against All Influenza Types and Subtypes". AZoNano. 18 April 2024. <https://www.azonano.com/news.aspx?newsID=11122>.

  • Chicago

    NanoViricides, Inc. "NanoViricides Developing FluCide to Work Against All Influenza Types and Subtypes". AZoNano. https://www.azonano.com/news.aspx?newsID=11122. (accessed April 18, 2024).

  • Harvard

    NanoViricides, Inc. 2019. NanoViricides Developing FluCide to Work Against All Influenza Types and Subtypes. AZoNano, viewed 18 April 2024, https://www.azonano.com/news.aspx?newsID=11122.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.